Hmdb loader
Survey
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2017-11-21 17:38:54 UTC
Update Date2022-03-07 03:18:14 UTC
HMDB IDHMDB0240231
Secondary Accession NumbersNone
Metabolite Identification
Common NameAcrivastine
DescriptionAcrivastine, also known as BW 825C or semprex, belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety. Acrivastine is a drug which is used for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. In humans, acrivastine is involved in the acrivastine h1-antihistamine action pathway. Acrivastine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Acrivastine.
Structure
Data?1563892733
Synonyms
ValueSource
(e)-6-((e)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acidChEBI
AcrivastinaChEBI
AcrivastinumChEBI
BW 825CChEBI
BW a825cChEBI
(e)-6-((e)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylateGenerator
Glaxo wellcome brand OF acrivastineHMDB
GlaxoSmithKline brand OF acrivastineHMDB
BW-825CHMDB
SemprexHMDB
BW 0270CHMDB
AcrivastineHMDB
Chemical FormulaC22H24N2O2
Average Molecular Weight348.4382
Monoisotopic Molecular Weight348.183778022
IUPAC Name(2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
Traditional Nameacrivastine
CAS Registry Number87848-99-5
SMILES
[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O
InChI Identifier
InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
InChI KeyPWACSDKDOHSSQD-IUTFFREVSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassStyrenes
Direct ParentStyrenes
Alternative Parents
Substituents
  • Styrene
  • Toluene
  • Pyridine
  • N-alkylpyrrolidine
  • Pyrrolidine
  • Heteroaromatic compound
  • Amino acid or derivatives
  • Tertiary amine
  • Tertiary aliphatic amine
  • Amino acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Organoheterocyclic compound
  • Azacycle
  • Organic oxide
  • Amine
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Hydrocarbon derivative
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+CBM193.930932474
Predicted Molecular Properties
PropertyValueSource
logP4.29ALOGPS
logP1.71ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)3.68ChemAxon
pKa (Strongest Basic)8.63ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.43 ŲChemAxon
Rotatable Bond Count6ChemAxon
Refractivity115.08 m³·mol⁻¹ChemAxon
Polarizability39.09 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
AllCCS[M+H]+186.82331661259
AllCCS[M-H]-191.7831661259
DeepCCS[M+H]+196.86530932474
DeepCCS[M-H]-194.4730932474
DeepCCS[M-2H]-227.4330932474
DeepCCS[M+Na]+203.92430932474
AllCCS[M+H]+186.832859911
AllCCS[M+H-H2O]+183.632859911
AllCCS[M+NH4]+189.832859911
AllCCS[M+Na]+190.632859911
AllCCS[M-H]-191.832859911
AllCCS[M+Na-2H]-191.932859911
AllCCS[M+HCOO]-192.232859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Acrivastine[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O4049.7Standard polar33892256
Acrivastine[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O2789.2Standard non polar33892256
Acrivastine[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O2937.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Acrivastine,1TMS,isomer #1CC1=CC=C(/C(=C\CN2CCCC2)C2=CC=CC(/C=C/C(=O)O[Si](C)(C)C)=N2)C=C13228.4Semi standard non polar33892256
Acrivastine,1TBDMS,isomer #1CC1=CC=C(/C(=C\CN2CCCC2)C2=CC=CC(/C=C/C(=O)O[Si](C)(C)C(C)(C)C)=N2)C=C13457.1Semi standard non polar33892256
Spectra
Biological Properties
Cellular LocationsNot Available
Biospecimen LocationsNot Available
Tissue LocationsNot Available
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB09488
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID4447574
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkAcrivastine
METLIN IDNot Available
PubChem Compound5284514
PDB IDNot Available
ChEBI ID83168
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Bojkowski CJ, Gibbs TG, Hellstern KH, Major EW, Mullinger B: Acrivastine in allergic rhinitis: a review of clinical experience. J Int Med Res. 1989;17 Suppl 2:54B-68B. [PubMed:2570003 ]